Novartis offers to acquire CellforCure

1 Jan 2019

Proposed acquisition will expand manufacturing capacity for innovative cell and gene therapies.

Novartis has announced an offer to acquire CellforCure from LFB. CellforCure, a French company, is one of the first and largest CDMOs producing cell and gene therapies in Europe.

Novartis offers to acquire CellforCure

Under the proposed agreement, Novartis would acquire the share capital of CellforCure from LFB including the cell and gene manufacturing facility located in Les Ulis and the related adjacent land. If the offer is accepted, CellforCure would become a wholly owned Novartis manufacturing site, joining the network of cell and gene therapy sites including Morris Plains, New Jersey, USA and Stein, Switzerland, where construction continues to progress as planned.

In July 2018, Novartis signed an agreement with CellforCure to produce CAR-T cell therapies including Kymriah (tisagenlecleucel), the first CAR-T cell therapy approved by the FDA and indicated for two distinct, difficult-to-treat cancers in the US, European Union, Switzerland, Canada and Australia. Novartis and CellforCure have successfully completed technology transfer and Kymriah clinical supply production is expected to begin by mid-2019. The proposed acquisition of CellforCure is another example of continued commitment by Novartis to investing in cell and gene therapies as well as in France.

Novartis has made several steps recently to strengthen and expand its cell and gene manufacturing, including signing a strategic licensing, collaboration and share purchase agreement with Cellular Biomedicine Group (CBMG) to manufacture and supply Kymriah in China; expanding an alliance with the Fraunhofer Institute in Germany to support manufacturing for clinical trials and post-approval manufacturing; and a contract manufacturing collaboration in Japan.

Novartis Global Head of Technical Operations Steffen Lang said: "The proposed acquisition of CellforCure is another strategic step in our pursuit of additional manufacturing capacity to make our transformational CAR-T cell therapy Kymriah available to more patients in need around the world. If completed, this acquisition also would potentially increase manufacturing capacity for other cell and gene therapies in the Novartis pipeline. We are excited about the possibility of adding the significant experience of CellforCure to our existing leadership in pioneering research, development and supply of cell and gene therapies."

Read More

Related tags

Market News

Related news

Specialist API CDMO acquired by GHO Capital

Specialist API CDMO acquired by GHO Capital

16 Mar 2019

Future plan is to extend Sterling’s international presence to meet increasing demand from customers worldwide.

Read more 
Bringing next generation single-use sensor technologies to the life science market

Bringing next generation single-use sensor technologies to the life science market

14 Mar 2019

Pall and Broadley-James’ combined expertise proves complementary in addressing critical customer pain points in modern bioprocessing.

Read more 
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

13 Mar 2019

Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.

Read more 
TraceLink submits an interoperable blockchain network solution for FDA DSCSA Pilot Project Program

TraceLink submits an interoperable blockchain network solution for FDA DSCSA Pilot Project Program

12 Mar 2019

Trace Histories is a purpose-built distributed ledger solution for ensuring patient safety by 2023 DSCSA deadline.

Read more 
Overcoming lyophilization challenges at Interphex 2019

Overcoming lyophilization challenges at Interphex 2019

10 Mar 2019

Line of Sight approach to freeze-drying enables organizations to bring pharmaceutical products safely and quickly to market.

Read more 
Catalent invests over $27 million to commercialize Zydis Ultra

Catalent invests over $27 million to commercialize Zydis Ultra

7 Mar 2019

Zydis Ultra allows a patented and innovative drug coating to be introduced during a product’s formulation, enabling the dosage of active ingredient to be up to four times higher than a conventional Zydis ODT.

Read more 
Novel systems for membrane chromatography

Novel systems for membrane chromatography

6 Mar 2019

Optimally run membrane chromatography processes will provide higher productivity, smaller-scale operations and increased robustness.

Read more 
Lilly to introduce lower-priced insulin

Lilly to introduce lower-priced insulin

5 Mar 2019

Authorized generic version of Humalog will be available in US pharmacies at 50% lower list price.

Read more 
Biogen acquisition boosts its ophthalmology pipeline

Biogen acquisition boosts its ophthalmology pipeline

4 Mar 2019

Nightstar Therapeutics has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.

Read more 
Uniqsis expands LED photoreactor range

Uniqsis expands LED photoreactor range

3 Mar 2019

The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.

Read more